Literature DB >> 8122300

Aluminum toxicity in patients with chronic renal failure.

A C Alfrey1.   

Abstract

During the past two decades, in association with the commencement of chronic dialysis therapy and prolongation of the uremic state, aluminum toxicity has represented a major cause of morbidity and mortality in uremic patients. The uremic patient has been found to be at higher risk of aluminum loading and toxicity from various sources of parenteral exposure, enhanced gastrointestinal absorption, and compromised ability to eliminate any systemically administered aluminum due to renal impairment. However, the potential sources of aluminum exposure and loading resulting in toxicity in uremic patients have recently been identified. As a result, this toxicity can largely be prevented by eliminating aluminum from the water used to prepare the dialysate, substituting calcium-containing phosphate-binding agents for those containing aluminum, and strict avoidance of the concomitant use of citrate- and aluminum-containing compounds. Thus, in the future, aluminum toxicity should represent a rare and unusual side effect in dialyzed uremic patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8122300     DOI: 10.1097/00007691-199312000-00025

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  12 in total

Review 1.  Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide.

Authors:  Daniel Krewski; Robert A Yokel; Evert Nieboer; David Borchelt; Joshua Cohen; Jean Harry; Sam Kacew; Joan Lindsay; Amal M Mahfouz; Virginie Rondeau
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2007       Impact factor: 6.393

Review 2.  Phosphate binders in patients with chronic kidney disease.

Authors:  Samuel Chan; Kenneth Au; Ross S Francis; David W Mudge; David W Johnson; Peter I Pillans
Journal:  Aust Prescr       Date:  2017-02-01

3.  Effect of aluminum consumption on the vestibulo-ocular reflex.

Authors:  O Mameli; M A Caria; P Melis; P Zambenedetti; M Ramila; P Zatta
Journal:  Metab Brain Dis       Date:  2006-07-20       Impact factor: 3.584

4.  The top 10 things nephrologists wish every primary care physician knew.

Authors:  Neil M Paige; Glenn T Nagami
Journal:  Mayo Clin Proc       Date:  2009-02       Impact factor: 7.616

5.  Sevelamer, a phosphate-binding polymer, is a non-absorbed compound.

Authors:  Melissa A Plone; John S Petersen; David P Rosenbaum; Steven K Burke
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 6.  Management of chronic kidney disease-mineral and bone disorder: Korean working group recommendations.

Authors:  Eunah Hwang; Bum Soon Choi; Kook-Hwan Oh; Young Joo Kwon; Gheun-Ho Kim
Journal:  Kidney Res Clin Pract       Date:  2015-02-24

Review 7.  Lanthanum carbonate: safety data after 10 years.

Authors:  Alastair J Hutchison; Rosamund J Wilson; Svetlana Garafola; John Brian Copley
Journal:  Nephrology (Carlton)       Date:  2016-12       Impact factor: 2.506

Review 8.  Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): Current Perspectives.

Authors:  Bala Waziri; Raquel Duarte; Saraladevi Naicker
Journal:  Int J Nephrol Renovasc Dis       Date:  2019-12-24

Review 9.  Phosphate control in dialysis.

Authors:  Adamasco Cupisti; Maurizio Gallieni; Maria Antonietta Rizzo; Stefania Caria; Mario Meola; Piergiorgio Bolasco
Journal:  Int J Nephrol Renovasc Dis       Date:  2013-10-04

Review 10.  Aluminium toxicosis: a review of toxic actions and effects.

Authors:  Ikechukwu Onyebuchi Igbokwe; Ephraim Igwenagu; Nanacha Afifi Igbokwe
Journal:  Interdiscip Toxicol       Date:  2020-02-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.